Using companion and coupled diagnostics within strategy to personalize targeted medicines
Singer, Donald R. J. and Watkins, John. (2012) Using companion and coupled diagnostics within strategy to personalize targeted medicines. Personalized Medicine, Vol.9 (No.7). pp. 751-761. ISSN 1741-0541Full text not available from this repository.
Official URL: http://dx.doi.org/10.2217/pme.12.86
Regulatory authorities expect the pharmaceutical and biotechnology industries to accelerate their development of companion diagnostics and companion therapeutics towards the goal of personalized medicine, and expect health services to fund, prescribers to adopt and patients to accept these new therapeutic technologies. Expected benefits from more systematic development of combination products (companion diagnostic and its companion therapeutic) are expected to include safer and improved clinical and cost-effective use of medicines, more efficient patient selection for clinical trials, more cost-effective treatment pathways for health services, and a more profitable approach for drug developers. This review discusses challenges to timely development of companion diagnostics and provides case studies of single and multiple protein and genetic biomarkers of clinical response and risk of adverse drug effects.
|Item Type:||Journal Article|
|Divisions:||Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Medicine > Warwick Medical School
|Journal or Publication Title:||Personalized Medicine|
|Publisher:||Future Medicine Ltd.|
|Page Range:||pp. 751-761|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)